ANCON Medical has developed a revolutionary technology called Nanoparticle Biomarker Tagging (NBT) that gives medical professionals the capability to detect deadly diseases in a patient’s breath.
Please note, this technology is in trial stage and not yet available as a commercial product. Further information may be obtained by getting in contact.
No matter what the disease, an early diagnosis always gives medical personnel more opportunities for treatment and prevention. NBT technology offers powerful capabilities to screen for a wide range of diseases with unprecedented sensitivity that makes detection possible at some of the earliest instances of exposure or infection.
The NBT device detects biomarkers, which act as chemical signatures for diseases, through the exhaled breath of an individual.
The sensitivity and selectivity of the Ancon Medical NBT device is unmatched by other similar breath detection technology. Tests at the Boulby Underground Laboratory in 2012 showed that NBT technology can measure down to one ion in 10,000 cubic centimeters, giving the device a sensitivity that could be measured down to a single molecule.
This sensitivity can mean the difference in weeks or months for a diagnosis. This head start can give doctors and healthcare professionals an advantage in treatment and therapy for a wide range of diseases, including:
Lung cancer has a low survival rate, but studies show that with early treatment, 57% of patients can survive for longer than 5 years, whereas only 9% survive if treatment occurs after symptoms emerge. Currently, screening for lung cancer requires expensive CT scans, and with there being such a wide range of at-risk individuals, the costs, equipment and invasiveness of the tests leave many lung cancer patients undiagnosed until symptoms emerge. With the NBT, mass screenings could help doctors discover the disease at much earlier stages, leading to earlier treatment that can save lives.
The shocking development of the Ebola virus in 2014 shows how crucial early detection of the virus is to prevent its quick spread. The unprecedented sensitivity of NBT technology would allow for detection of the Ebola virus within 24 to 72 hours of exposure, before the individual is showing symptoms of the disease. Early detection not only gives exposed individuals more treatment options, but it’s also crucial in slowing the spread of the disease. Once the biomarker is discovered, ANCON Medical’s NBT device would be a powerful tool in preventing and containing outbreaks.
Tuberculosis is one of the world’s leading causes of death and a forefront healthcare issue for the developing world. TB kills 1.5 million people every year and it’s believed that 3 million go undiagnosed, making disease diagnosis a central part of the strategy to fight TB. Currently, diagnosing TB requires a complicated procedure, including blood tests and examination of chest x-rays, which requires highly-trained medical personnel. The NBT device is the ideal weapon to fight a disease like TB, allowing for mass screenings by use of a simple breath test that can be administered by non-medical staff and volunteers, with results in less than one hour.